Manufacturer expands access to prostate drug
Do you have any prostate cancer patients whose treatments have failed? If so, there's a new option they can try. It's satraplatin, which GPC Biotech is offering under an expanded-access program. Called the Satraplatin Expanded Rapid Access (SPERA) protocol, the program offers hormone-refractory prostate cancer patients whose first-line chemotherapy has failed the investigational drug on a gratis basis. Satraplatin is a fourth-generation oral drug in the platinum family of compounds. For more information, contact 1-(800) 349-8086 or
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
